Interferon-α for Viral Hepatitis
IFN-alpha has emerged as a promising treatment of chronic viral hepatitis. Although therapeutic response to IFN is far from universal, efficacy has been demonstrated; and studies combining IFN-alpha with other agents, as well as trials with new preparations of IFN-alpha, are under way. Children do n...
Gespeichert in:
| Veröffentlicht in: | Journal of pediatric gastroenterology and nutrition 1996-08, Vol.23 (2), p.93-106 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 106 |
|---|---|
| container_issue | 2 |
| container_start_page | 93 |
| container_title | Journal of pediatric gastroenterology and nutrition |
| container_volume | 23 |
| creator | Jonas, Maureen M |
| description | IFN-alpha has emerged as a promising treatment of chronic viral hepatitis. Although therapeutic response to IFN is far from universal, efficacy has been demonstrated; and studies combining IFN-alpha with other agents, as well as trials with new preparations of IFN-alpha, are under way. Children do not represent a large part of the identified population with chronic viral hepatitis. Yet children, by simple virtue of age, are more recently infected. In addition, longer life expectancies can be expected to be associated with greater morbidity from chronic viral hepatitis. Children seem to tolerate therapy with IFN-alpha well. Treatment of children with chronic viral hepatitis should be strongly considered, with protocols designed to ascertain specific pediatric safety and efficacy. |
| doi_str_mv | 10.1097/00005176-199608000-00001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78414969</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78414969</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4631-d74bf69a20c2be9728e8b18ab7bbf8adae627f6b0dcbdc336bb3b6ba93c4be123</originalsourceid><addsrcrecordid>eNp1kc1OAyEURonR1Fp9BJMxMe5QGBh-lsaobdLEjbolwEA6SjsVZtL4WL6IzyS1Y3eyIXz33HuTAwAFRtcYSX6D8qkwZxBLyZDIL7iN8AEY44owSAXCh2CMSs5hiTE7BicpvWWC0wqNwEiIilWcjMHFbNW56F1sV_D7q_BtLF6bqEMxdWvdNV2TTsGR1yG5s-GegJeH--e7KZw_Pc7ubufQUkYwrDk1nkldIlsaJ3kpnDBYaMON8ULX2rGSe2ZQbU1tCWHGEMOMlsRS43BJJuBqN3cd24_epU4tm2RdCHrl2j4pLiimkskMih1oY5tSdF6tY7PU8VNhpLZ21J8dtbfzG-Hcej7s6M3S1fvGQUeuXw51nawOPuqVbdIeI1giRnnG6A7btCHbS--h37ioFk6HbqH--xvyA5Ree_8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78414969</pqid></control><display><type>article</type><title>Interferon-α for Viral Hepatitis</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Jonas, Maureen M</creator><creatorcontrib>Jonas, Maureen M</creatorcontrib><description>IFN-alpha has emerged as a promising treatment of chronic viral hepatitis. Although therapeutic response to IFN is far from universal, efficacy has been demonstrated; and studies combining IFN-alpha with other agents, as well as trials with new preparations of IFN-alpha, are under way. Children do not represent a large part of the identified population with chronic viral hepatitis. Yet children, by simple virtue of age, are more recently infected. In addition, longer life expectancies can be expected to be associated with greater morbidity from chronic viral hepatitis. Children seem to tolerate therapy with IFN-alpha well. Treatment of children with chronic viral hepatitis should be strongly considered, with protocols designed to ascertain specific pediatric safety and efficacy.</description><identifier>ISSN: 0277-2116</identifier><identifier>EISSN: 1536-4801</identifier><identifier>DOI: 10.1097/00005176-199608000-00001</identifier><identifier>PMID: 8856573</identifier><identifier>CODEN: JPGND6</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott-Raven Publishers</publisher><subject>Antibodies - blood ; Biological and medical sciences ; Child ; Chronic Disease ; Hepatitis B - drug therapy ; Hepatitis C - drug therapy ; Hepatitis D - drug therapy ; Hepatitis, Viral, Human - drug therapy ; Hepatitis, Viral, Human - economics ; Human viral diseases ; Humans ; Infectious diseases ; Interferon Type I - adverse effects ; Interferon Type I - economics ; Interferon Type I - therapeutic use ; Interferon-alpha - immunology ; Interferon-alpha - physiology ; Medical sciences ; Recombinant Proteins ; Viral diseases ; Viral hepatitis</subject><ispartof>Journal of pediatric gastroenterology and nutrition, 1996-08, Vol.23 (2), p.93-106</ispartof><rights>Lippincott-Raven Publishers</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4631-d74bf69a20c2be9728e8b18ab7bbf8adae627f6b0dcbdc336bb3b6ba93c4be123</citedby><cites>FETCH-LOGICAL-c4631-d74bf69a20c2be9728e8b18ab7bbf8adae627f6b0dcbdc336bb3b6ba93c4be123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3190647$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8856573$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jonas, Maureen M</creatorcontrib><title>Interferon-α for Viral Hepatitis</title><title>Journal of pediatric gastroenterology and nutrition</title><addtitle>J Pediatr Gastroenterol Nutr</addtitle><description>IFN-alpha has emerged as a promising treatment of chronic viral hepatitis. Although therapeutic response to IFN is far from universal, efficacy has been demonstrated; and studies combining IFN-alpha with other agents, as well as trials with new preparations of IFN-alpha, are under way. Children do not represent a large part of the identified population with chronic viral hepatitis. Yet children, by simple virtue of age, are more recently infected. In addition, longer life expectancies can be expected to be associated with greater morbidity from chronic viral hepatitis. Children seem to tolerate therapy with IFN-alpha well. Treatment of children with chronic viral hepatitis should be strongly considered, with protocols designed to ascertain specific pediatric safety and efficacy.</description><subject>Antibodies - blood</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Chronic Disease</subject><subject>Hepatitis B - drug therapy</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis D - drug therapy</subject><subject>Hepatitis, Viral, Human - drug therapy</subject><subject>Hepatitis, Viral, Human - economics</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Interferon Type I - adverse effects</subject><subject>Interferon Type I - economics</subject><subject>Interferon Type I - therapeutic use</subject><subject>Interferon-alpha - immunology</subject><subject>Interferon-alpha - physiology</subject><subject>Medical sciences</subject><subject>Recombinant Proteins</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><issn>0277-2116</issn><issn>1536-4801</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1OAyEURonR1Fp9BJMxMe5QGBh-lsaobdLEjbolwEA6SjsVZtL4WL6IzyS1Y3eyIXz33HuTAwAFRtcYSX6D8qkwZxBLyZDIL7iN8AEY44owSAXCh2CMSs5hiTE7BicpvWWC0wqNwEiIilWcjMHFbNW56F1sV_D7q_BtLF6bqEMxdWvdNV2TTsGR1yG5s-GegJeH--e7KZw_Pc7ubufQUkYwrDk1nkldIlsaJ3kpnDBYaMON8ULX2rGSe2ZQbU1tCWHGEMOMlsRS43BJJuBqN3cd24_epU4tm2RdCHrl2j4pLiimkskMih1oY5tSdF6tY7PU8VNhpLZ21J8dtbfzG-Hcej7s6M3S1fvGQUeuXw51nawOPuqVbdIeI1giRnnG6A7btCHbS--h37ioFk6HbqH--xvyA5Ree_8</recordid><startdate>199608</startdate><enddate>199608</enddate><creator>Jonas, Maureen M</creator><general>Lippincott-Raven Publishers</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199608</creationdate><title>Interferon-α for Viral Hepatitis</title><author>Jonas, Maureen M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4631-d74bf69a20c2be9728e8b18ab7bbf8adae627f6b0dcbdc336bb3b6ba93c4be123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Antibodies - blood</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Chronic Disease</topic><topic>Hepatitis B - drug therapy</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis D - drug therapy</topic><topic>Hepatitis, Viral, Human - drug therapy</topic><topic>Hepatitis, Viral, Human - economics</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Interferon Type I - adverse effects</topic><topic>Interferon Type I - economics</topic><topic>Interferon Type I - therapeutic use</topic><topic>Interferon-alpha - immunology</topic><topic>Interferon-alpha - physiology</topic><topic>Medical sciences</topic><topic>Recombinant Proteins</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jonas, Maureen M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pediatric gastroenterology and nutrition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jonas, Maureen M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interferon-α for Viral Hepatitis</atitle><jtitle>Journal of pediatric gastroenterology and nutrition</jtitle><addtitle>J Pediatr Gastroenterol Nutr</addtitle><date>1996-08</date><risdate>1996</risdate><volume>23</volume><issue>2</issue><spage>93</spage><epage>106</epage><pages>93-106</pages><issn>0277-2116</issn><eissn>1536-4801</eissn><coden>JPGND6</coden><abstract>IFN-alpha has emerged as a promising treatment of chronic viral hepatitis. Although therapeutic response to IFN is far from universal, efficacy has been demonstrated; and studies combining IFN-alpha with other agents, as well as trials with new preparations of IFN-alpha, are under way. Children do not represent a large part of the identified population with chronic viral hepatitis. Yet children, by simple virtue of age, are more recently infected. In addition, longer life expectancies can be expected to be associated with greater morbidity from chronic viral hepatitis. Children seem to tolerate therapy with IFN-alpha well. Treatment of children with chronic viral hepatitis should be strongly considered, with protocols designed to ascertain specific pediatric safety and efficacy.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott-Raven Publishers</pub><pmid>8856573</pmid><doi>10.1097/00005176-199608000-00001</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-2116 |
| ispartof | Journal of pediatric gastroenterology and nutrition, 1996-08, Vol.23 (2), p.93-106 |
| issn | 0277-2116 1536-4801 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78414969 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Antibodies - blood Biological and medical sciences Child Chronic Disease Hepatitis B - drug therapy Hepatitis C - drug therapy Hepatitis D - drug therapy Hepatitis, Viral, Human - drug therapy Hepatitis, Viral, Human - economics Human viral diseases Humans Infectious diseases Interferon Type I - adverse effects Interferon Type I - economics Interferon Type I - therapeutic use Interferon-alpha - immunology Interferon-alpha - physiology Medical sciences Recombinant Proteins Viral diseases Viral hepatitis |
| title | Interferon-α for Viral Hepatitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T09%3A43%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interferon-%CE%B1%20for%20Viral%20Hepatitis&rft.jtitle=Journal%20of%20pediatric%20gastroenterology%20and%20nutrition&rft.au=Jonas,%20Maureen%20M&rft.date=1996-08&rft.volume=23&rft.issue=2&rft.spage=93&rft.epage=106&rft.pages=93-106&rft.issn=0277-2116&rft.eissn=1536-4801&rft.coden=JPGND6&rft_id=info:doi/10.1097/00005176-199608000-00001&rft_dat=%3Cproquest_cross%3E78414969%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78414969&rft_id=info:pmid/8856573&rfr_iscdi=true |